1370468-13-5Relevant articles and documents
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms
Tong, Ling,Yu, Wensheng,Chen, Lei,Selyutin, Oleg,Dwyer, Michael P.,Nair, Anilkumar G.,Mazzola, Robert,Kim, Jae-Hun,Sha, Deyou,Yin, Jingjun,Ruck, Rebecca T.,Davies, Ian W.,Hu, Bin,Zhong, Bin,Hao, Jinglai,Ji, Tao,Zan, Shuai,Liu, Rong,Agrawal, Sony,Xia, Ellen,Curry, Stephanie,McMonagle, Patricia,Bystol, Karin,Lahser, Frederick,Carr, Donna,Rokosz, Laura,Ingravallo, Paul,Chen, Shiying,Feng, Kung-I,Cartwright, Mark,Asante-Appiah, Ernest,Kozlowski, Joseph A.
, p. 290 - 306 (2017/04/26)
We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a "flat" GT1 mutant profile. This NS5A inhibitor contains a unique tetracyclic indole core while maintaining the imidazole-proline-valine Moc motifs of our previous NS5A inhibitors. Compound 40 is currently in early clinical trials and is under evaluation as part of an all-oral DAA regimen for the treatment of chronic HCV infection.
TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
-
, (2012/04/17)
The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.